Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of medicinal products in ATC group A02 (drugs for acid related disorders)
At the request of the Danish Medicines Agency, the Reimbursement Committee has reassessed the reimbursement status of medicinal products in ATC group A02 (drugs for acid related disorders). The Reimbursement Committee recommends that some of these medicinal products should no longer be eligible for general or general conditional reimbursement.
The Reimbursement Committee's recommendation can be read in the factbox to the right (in Danish only).
On 14 December 2009, the Danish Medicines Agency launched a consultation of the companies whose medicinal products are comprised by the Committee's recommendation. A copy of the Danish Medicines Agency's letter can be seen in the factbox to the right (in Danish only).
The consultation is open until 15 March 2010.
Moreover, we have sent a notification about the Reimbursement Committee's recommendation to
the Danish Endocrine Society, Danish Society for Gastroenterology, Danish Gerontological Society, Danish Surgical Society, Danish Medical Society, Danish Paediatric Society, Danish College of General Practitioners, Danish Society of Geriatrics, Danish Association for the Study of the Liver, Danish Society of Internal Medicine, Danish Society for Clinical Nutrition and Metabolism, Danish Society of Clinical Pharmacology and Danish Society of Clinical Oncology. In addition, the National Board of Health and the Institute for Rational Pharmacotherapy have been briefed.
For further information, please contact the Reimbursement Department, email@example.com.
Danish Medicines Agency, 15 December 2009